Are you ready for the oncology patent cliff?
This article was originally published in Scrip
New analysis has highlighted a looming patent cliff in the oncology sector. Datamonitor Healthcare's newly launched Oncology ExpiryView tool indicates that after a period of relative calm over the next few years, 2018-2022 will see $32bn of sales of cancer treatments in the seven major market at risk as a result of patent expiries. Roche will be particularly threatened, followed by Celgene and then Novartis.